EnColl's Collagen Technology
Papain, an enzyme extracted from papaya, is known to break the cleavage sites neighboring the disulfide bonds of cysteine. Papain has also been reported to have a lytic (destructive) effect of elastin and bound antibodies the contaminants that are difficult to remove from purified collagen (Coulson, Biochim. Biophys. Acta 237:378, 1971; and Smith et al., Nature 198:1311-2, 1963).
After the purification process, EnColl’s collagen is further bioactivated by varied degrees of controlled modification of phosphorylation. Purified collagen can be chemically-modified by covalently binding phosphates to hydroxyl groups of hydroxylated amino acids. This reaction likely involves covalent bonding of phosphate to hydroxyl group of serine, tyrosine and/or threonine, hydroxylysine and hydroxyproline. The reaction is controllable to achieve different degrees of bioactivity for varied applications. Encoll’s phosphorylated collagen renders unique abilities in the growth of soft or hard tissue as needed by the physiological system.
EnColl's Competitive Advantage
The unique post-translational modification (phosphorylation) of Collagen through EnColl’s patented manufacturing process gives added advantage by enhanced bioactivity useful for a variety of medical applications.
Other common benefits of EnColl’s collagen (over other commercially available collagen) in the market are:
- Biocompatibility
- Least Immunogenicity
- Bioresorbability
- Cell Attractability
- Hemostastic Ability
- Structural Stability
- Target Specificity
- Slow and Sustained Release of Bound Drugs
- Increased solubility & Optical clarity at neutral pH after chemical modification
- Enhanced bonding to active drugs or factors
- Available in powder, tubular, gel, film, surface coating, sponge or in fabric form
Management
Dr. S. Gunasekaran
Founder & CEO of Encoll Corp
Professional Employment History
Dr. Guna is the founder and CEO of Encoll Corp. (founded in 1994). He has three US Patents and has fifteen publications in the area of collagen and biomaterials since the founding of EnColl. Previously Dr. Guna was a consultant and scientist for Pfizer, Orthopedic Division and was employed by University of Arizona, Department of Surgery as a Research Scientist and Lecturer. Dr Guna holds a Ph.D. in Biological-chemistry/Neuro-physiology.
Areas of Expertise
Dr. Guna is accomplished in areas basic research involving cell culture, pre-clinical animal model development, protein processing, pharmaceutical manufacturing, and the strategic development of ethical drugs and regulatory approved medical devices. Additionally, his basic research included work in cell culture and animal model development. Dr. Guna directed a number of programs for successful development of ethical drug and device product as the head of project design groups and management teams. He has completed numerous pre-clinical study designs and study executions.
Our Team Members
S. Gunasekaran, PhD
President
Murugan Gunasekaran
VP Sales & Marketing
Vedha Muthu
Regulatory Affairs
Kalai Gunasekaran
QC & Executive Board
Lily Tran
QC inspector
Ken Wing
Advisory Board
Corine Klingbeil, PhD
Advisory Board